Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study aligns with the strategic plan of New York-Presbyterian Hospital (NYPH) to reduce
allogeneic blood product use and decrease unnecessary laboratory costs. One of the NYPH
Quality and Patient Safety Goals for 2013 was to improve the appropriate use of transfusion
guidelines and reduce unnecessary red blood cell (RBC) transfusions. Further, this study will
help to answer whether RiaSTAP is a more effective product to treat bleeding than
cryoprecipitate. In addition, this trial will provide investigators with preliminary data to
apply for future federal funding opportunities, such as the National Heart Lung and Blood
Institute sponsored R21 grant (PAR-13-025) that encourages research grant applications from
investigators who propose to study research topics in blood banking and transfusion medicine
aimed at improving the safety and availability of the blood supply and the practice of
transfusion medicine. The investigators anticipate future follow-on studies further
investigating fibrinogen concentrate and other similar therapeutics in other perioperative
populations, such as in postpartum hemorrhage or surgical ICU settings. Finally, this study
involves the use of a safer therapeutic, fibrinogen concentrate, to improve patient care and
patient safety. This product does not require the time-intensive process of thawing;
therefore, delays in patient care can be avoided by having the product readily available in
the OR.